Association of PD-L1 and HIF-1 α Coexpression with Poor Prognosis in Hepatocellular Carcinoma.

CONCLUSION: We demonstrated that HCC patients with co-overexpression of PD-L1 and HIF-1α in tumor tissue had a significantly higher risk of recurrence or metastasis and death compared with others. Therefore, more frequent follow-up is needed for patients with co-overexpression of PD-L1 and HIF-1α. At the same time, a combinational therapy with HIF-1α inhibitors in conjunction with PD-L1 blockade may be beneficial for HCC patients with co-overexpression in the future.
PMID: 29525633 [PubMed - as supplied by publisher]

Source: Translational Oncology - March 8, 2018 Category: Cancer & Oncology Authors: Dai X, Pi G, Yang SL, Chen GG, Liu LP, Dong HH Tags: Transl Oncol Source Type: research